VCX and B-cell chronic lymphocytic leukemia: Our findings that VCX is a novel autophagy inhibitor and sensitizes CLL cells to IBR provide a potential new mechanism that at least partially explains the marked antitumor activity of VCX seen on combination therapies in the clinic [25,26].